David U’Prichard, Chairman of the Board of Directors of Cyclacel Pharmaceuticals, Inc. to Take Medical Leave of Absence from Board and from All Committees
August 26, 2020 at 05:10 pm EDT
Share
Dr. David U’Prichard, Chairman of the Board of Directors of Cyclacel Pharmaceuticals, Inc. has informed the Board of his intent to take a medical leave of absence from his service on the Board and from all committees thereof. Effective August 26, 2020, Dr. Christopher Henney, Vice Chairman of the Board, will serve as Chairman of the Board during Dr. U’Prichard’s absence.
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
David U’Prichard, Chairman of the Board of Directors of Cyclacel Pharmaceuticals, Inc. to Take Medical Leave of Absence from Board and from All Committees
CYCLACEL PHARMACEUTICALS, INC. 
